<html>
<head>
<title>PubMed</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<link rel="stylesheet" type="text/css">
<script language="JavaScript" type="text/JavaScript">
<!--
function MM_openBrWindow(theURL,winName,features) { //v2.0
  window.open(theURL,winName,features);
}
//-->
</script>
</head>

<body bgcolor="B6B6B6">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="880000" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><font color="#FFFFFF"><a name="Top"></a><img src="../Assets/DISHtitle.gif" width="530" height="50"></font></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="37" width="54"></td>
    <td valign="top" width="723"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_DiabetesandISH.html"><img src="../Assets/PM1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_DiabetesandISH.html"><img src="../Assets/PM2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_DiabetesandISH.html"><img src="../Assets/PM3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_DiabetesandISH.html"><img src="../Assets/PM4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_DiabetesandISH.html"><img src="../Assets/PM5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_DiabetesandISH.html"><img src="../Assets/PM6.gif" width="121" height="37" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="50"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/PMheader.gif" width="330" height="50" align="baseline"><img src="../Assets/PMheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469"></td>
    <td valign="middle" bgcolor="#FFFFCC"> 
      <div align="center"><br>
        <table width="88%" border="0" height="508">
          <tr>
            <td bgcolor="#FFFFCC"> 
              <div align="center"> 
                <div align="center"> 
                  <p align="left"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><font color="663333">Curb 
                    JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black 
                    H, et al. Effect of diuretic-based antihypertensive treatment 
                    on cardiovascular disease risk in older diabetic patients 
                    with isolated systolic hypertension. Systolic Hypertension 
                    in the Elderly Program Cooperative Research Group [published 
                    erratum appears in JAMA 1997 May 7;277(17):1356]. Jama 1996;276(23):1886-92.</font></b></font></p>
                  <p align="left"><font color="663333" size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Abstract</b>:<br>
                    </font><font color="663333" size="2" face="Verdana, Arial, Helvetica, sans-serif">OBJECTIVE: 
                    To assess the effect of low-dose, diuretic-based antihypertensive 
                    treatment on major cardiovascular disease (CVD) event rates 
                    in older, non-insulin-treated diabetic patients with isolated 
                    systolic hypertension (ISH), compared with nondiabetic patients. 
                    DESIGN: Double-blind, randomized, placebo-controlled trial: 
                    the Systolic Hypertension in the Elderly Program (SHEP). SETTING: 
                    Multiple clinical and support centers in the United States. 
                    PARTICIPANTS: A total of 4736 men and women aged 60 years 
                    and older at baseline with ISH (systolic blood pressure [BP], 
                    &gt; or = 160 mm Hg; diastolic BP, &lt;90 mm Hg) at baseline, 
                    583 non-insulin-dependent diabetic patients and 4149 nondiabetic 
                    patients (4 additional patients not so classifiable were randomized 
                    but not included in these analyses). Diabetes mellitus defined 
                    as physician diagnosis, taking oral hypoglycemic drugs, fasting 
                    glucose level of 7.8 mmol/L or more (&gt; or = 140 mg/dL), 
                    or any combination of these characteristics. INTERVENTION: 
                    The active treatment group received a low dose of chlorthalidone 
                    (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) 
                    or reserpine (0.05-0.10 mg/d) if needed. The placebo group 
                    received placebo and any active antihypertensive drugs prescribed 
                    by patient's private physician for persistently high BP. MAIN 
                    OUTCOME MEASURES: The 5-year rates of major CVD events, nonfatal 
                    plus fatal stroke, nonfatal myocardial infarction (MI) and 
                    fatal coronary heart disease (CHD), major CHD events, and 
                    all-cause mortality. RESULTS: The SHEP antihypertensive drug 
                    regimen lowered BP of both diabetic and nondiabetic patients, 
                    with few adverse effects. For both diabetic and nondiabetic 
                    patients, all outcome rates were lower for participants randomized 
                    to the active treatment group than for those randomized to 
                    the placebo group. Thus, 5-year major CVD rate was lower by 
                    34% for active treatment compared with placebo, both for diabetic 
                    patients (95% confidence interval [CI], 6%-54%) and nondiabetic 
                    patients (95% CI, 21%-45%). Absolute risk reduction with active 
                    treatment compared with placebo was twice as great for diabetic 
                    vs nondiabetic patients (101/1000 vs 51/1000 randomized participants 
                    at the 5-year follow-up), reflecting the higher risk of diabetic 
                    patients. CONCLUSION: Low-dose diuretic-based (chlorthalidone) 
                    treatment is effective in preventing major CVD events, cerebral 
                    and cardiac, in both non-insulin-treated diabetic and nondiabetic 
                    older patients with ISH. [<a href="#" onClick="MM_openBrWindow('Indiv_Curb1996.html','','status=yes,scrollbars=yes,resizable=yes,width=700,height=550')">See 
                    ACP Summary</a>] </font></p>
                </div>
                <p align="left">&nbsp;</p>
                </div>
              <p class="BEsection" align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></p>
              </td>
          </tr>
        </table>
        
      </div>
    </td>
        </tr>
  <tr> 
    <td height="28"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="ff4d4a"> 
            
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
